A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer
Open Access
- 13 April 2022
- journal article
- research article
- Published by Taylor & Francis in Drug Delivery
- Vol. 29 (1) , 1243-1256
Abstract
The present study aimed to evaluate the anti-tumor efficacy of the epidermal growth factor receptor (EGFR)-targeting recombinant fusion protein Fv-LDP-D3 and its antibody-drug conjugate Fv-LDP-D3-AE against esophageal cancer. Fv-LDP-D3, consisting of the fragment variable (Fv) of an anti-EGFR antibody, the apoprotein of lidamycin (LDP), and the third domain of human serum albumin (D3), exhibited a high binding affinity for EGFR-overexpressing esophageal cancer cells, inhibited EGFR phosphorylation and down-regulated inosine monophosphate dehydrogenase type II (IMPDH2) expression. Fv-LDP-D3 was taken up by cancer cells through intensive macropinocytosis; it inhibited the proliferation and induced the apoptosis of esophageal cancer cells. In vivo imaging revealed that Fv-LDP-D3 displayed specific tumor-site accumulation and a long-lasting retention over a 26-day period. Furthermore, Fv-LDP-D3-AE, a pertinent antibody-drug conjugate prepared by integrating the enediyne chromophore of lidamycin into the Fv-LDP-D3 molecule, displayed highly potent cytotoxicity, inhibited migration and invasion, induced apoptosis and DNA damage, arrested cells at G2/M phase, and caused mitochondrial damage in esophageal cancer cells. More importantly, both of Fv-LDP-D3 and Fv-LDP-D3-AE markedly inhibited the growth of esophageal cancer xenografts in athymic mice at well tolerated doses. The present results indicate that Fv-LDP-D3, and Fv-LDP-D3-AE exert prominent antitumor efficacy associated with targeting EGFR, suggesting their potential as promising candidates for targeted therapy against esophageal cancer.Keywords
Funding Information
- the Drug Innovation Major Project (2018ZX09711001-009-003)
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-030)
- National Natural Science Foundation of China (82173211)
This publication has 39 references indexed in Scilit:
- Epidermal growth factor receptor targeting in cancer: A review of trends and strategiesBiomaterials, 2013
- Single-chain Variable Fragment Albumin Fusions Bind the Neonatal Fc Receptor (FcRn) in a Species-dependent MannerJournal of Biological Chemistry, 2013
- Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumabOncology Reports, 2012
- Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic miceCancer Chemotherapy and Pharmacology, 2012
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and AntimetabolitesMolecular Cancer Therapeutics, 2012
- A Bispecific Enediyne-Energized Fusion Protein Containing Ligand-Based and Antibody-Based Oligopeptides against Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Shows Potent Antitumor ActivityClinical Cancer Research, 2010
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticlesJournal of Controlled Release, 2008
- Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinomaInternational Journal of Cancer, 2006
- EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagusInternational Journal of Cancer, 2005
- Solution structures of C-1027 apoprotein and its complex with the aromatized chromophoreJournal of Molecular Biology, 2001